Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

Other equities analysts have also recently issued research reports about the company. Lake Street Capital reduced their target price on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Ekso Bionics in a report on Tuesday, March 4th.

Ekso Bionics Trading Up 1.8 %

EKSO opened at $0.46 on Thursday. The firm has a 50 day simple moving average of $0.53 and a 200 day simple moving average of $0.75. Ekso Bionics has a fifty-two week low of $0.34 and a fifty-two week high of $1.53. The company has a market cap of $11.42 million, a price-to-earnings ratio of -0.71 and a beta of 1.43. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. On average, sell-side analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.